Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

(2012) J. A. Pollard et al.   BLOOD

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial

(2011) Brenda E. S. Gibson et al.   BRITISH JOURNAL OF HAEMATOLOGY

AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia

(2011) Todd M. Cooper et al.   CANCER

What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia?

(2011) Joseph G. Jurcic   Current Hematologic Malignancy Reports

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

(2010) B. Lowenberg et al.   BLOOD

Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission Rate

(2010) Jonas Abrahamsson et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials

(2010) A Sander et al.   LEUKEMIA

Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: A NOPHO-AML study

(2010) Lene Molgaard-Hansen et al.   PEDIATRIC BLOOD & CANCER

Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation

(2009) P Chevallier et al.   BONE MARROW TRANSPLANTATION

Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study

(2009) Christian M. Zwaan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Risk-Stratified Therapy and the Intensive Use of Cytarabine Improves the Outcome in Childhood Acute Myeloid Leukemia: The AML99 Trial From the Japanese Childhood AML Cooperative Study Group

(2009) Ichiro Tsukimoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin

(2008) M. B. Maniecki et al.   BLOOD

Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group

(2008) Richard Aplenc et al.   JOURNAL OF CLINICAL ONCOLOGY